July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Histology of myopic scleral staphylomas
Author Affiliations & Notes
  • Jost B Jonas
    Ophthalmology, Medical Faculty Mannheim-Heidelberg, Mannheim, Germany
  • Kyoko Ohno-Matsui
    Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Tokyo, Japan
  • Leonard Holbach
    Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
  • Songhomitra Panda-Jonas
    Ophthalmology, Medical Faculty Mannheim-Heidelberg, Mannheim, Germany
  • Footnotes
    Commercial Relationships   Jost Jonas, Patent holder with Biocompatibles UK Ltd. (Franham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and Patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; European Patent Number: 3 070 101). Advisor board member Abyss Processing Co (P); Kyoko Ohno-Matsui, None; Leonard Holbach, None; Songhomitra Panda-Jonas, Patent holder with Biocompatible UK Ltd. (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and (together with Rahul Jonas and Shefali Jonas) patent application with university of Heidelberg (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15 000 771.4). (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4354. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jost B Jonas, Kyoko Ohno-Matsui, Leonard Holbach, Songhomitra Panda-Jonas; Histology of myopic scleral staphylomas. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4354. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To histologically examine scleral staphylomata in highly myopic eyes

Methods : Sagittal histological sections of human globes enucleated due to malignant choroidal melanomas, or secondary angle-closure glaucoma were histomorphometrically examined

Results : Scleral staphylomas were detected in 6 eyes with a mean length of 29.3±3.3mm. The staphylomas were characterized by a relatively abrupt thinning of the sclera to about 50% of its value in the neighborhood of the staphyloma, a mean scleral thickness of 99±48µm (range:36-167µm) in the staphyloma region, a scleral thickness of 338±101µm (range:167-476µm) in the staphyloma vicinity, a normal Bruchs membrane thickness of 4.1±1.6µm (range:3.0-7.5µm), a normal choriocapillaris thickness of 5.1±2.4µm (range:0.00-7.2µm), and a normal retinal pigment epithelium cell density of 24.9±6.6 cells/480 µm length

Conclusions : A myopic scleral staphyloma is histologically characterized by an abrupt thinning of the sclera to less than 50% of the scleral thickness in the staphyloma vicinity, with normal values for Bruchs membrane thickness, choriocapillaris thickness and retinal pigment epithelium cell density. These data suggest that a myopic scleral staphyloma may primarily be due to a local structural weakness of the sclera leading to an outpouching of the normal Bruchs membrane with its adjacent retinal pigment epithelium and choriocapillaris.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×